Clinical Trials Logo

Filter by:
NCT ID: NCT03908242 Not yet recruiting - Diabetes Clinical Trials

Phase I Study of Continuous Administration of Salvianolic Acid A Tablet

Start date: April 8, 2019
Phase: Phase 1
Study type: Interventional

Salvianolic acid A has a variety of pharmacological effects, such as: anti-oxidation, scavenging oxygen free radicals, anti-fibrosis, anti-myocardial ischemia, anti-coagulation, anti-thrombosis, anti-tumor, etc. Professor Du Guanhua, at Institue of Materia Medica, Chinese Academy of Medical Sciences, first discovered that salvianolic acid A can alleviate diabetic complications and improve patients' quality of life. With the support of major national science and technology projects, the preclinical research work of salvianolic acid A was completed, and the application was approved by the State Food and Drug Administration (Clinical Approval No.: 2016L06293).The purpose of this study is to assess the safety,tolerability, and pharmacokinetics (PK) of an extended dosing regimen ofsalvianolic acid A: open label, continuous subcutaneous infusion for 7 days were tested as ascending doses of salvianolic acid A from 90mg up to 180 mg.

NCT ID: NCT04823351 Not yet recruiting - Covid19 Clinical Trials

Clinical Efficiency of Surgical Masks and Filtering Face-piece 2 Masks

Start date: April 8, 2021
Phase: N/A
Study type: Interventional

Recent results demonstrated an increased risk of COVID-19 infection among healthcare workers (HCW), particularly when access to personal protective equipment (PPE) was inadequate. (ref). During the COVID-19 pandemic, access to PPE has become complicated by a surge in worldwide demand combined with production limitations and logistical barriers. Since their introduction in hospitals in the 1990s, filtering facepiece (FFP) masks, mostly of the FFP2 type, are used by HCWs to protect themselves against bioaerosols due to tuberculosis, measles, and selected respiratory viruses. The COVID-19 pandemic has sparked debate around reasonable and safe use of the different types of face masks to protect the HCWs who provide direct care for COVID-19 patients. At the heart of the discussion are the respective contributions to SARS-CoV-2 transmissions by droplets and aerosols, and the corresponding risk levels resulting in COVID-19 infection. The objective is to perform a cluster-randomized, parallel, controlled, non-inferiority study among Swiss nursing and retirement homes to evaluate the efficacy of surgical masks vs. FFP2 masks during patient care and prospectively observe possible infections amongst both vaccinated and unvaccinated staff. Staff in nursing homes will be randomized to use either surgical or FFP2 masks for patient care consistently. Considering an attack rate of 0.8% over three months among healthcare workers, a non-inferiority margin of 5%, and an intracluster variability of 0.01, - we require a minimum of 625 participants per group. The COVID-19 attack rate will be tested by initial serology testing and weekly pooled saliva specimen for SARS-CoV-2 testing. (Re)-Infections will be tracked by weekly pooled saliva-based PCR testing. Exposure to COVID-19 other than during work time will be explored by questionnaires and focus group discussions.

NCT ID: NCT05330559 Not yet recruiting - Clinical trials for Patients With Radiological, Clinical and Anamnestic Picture Compatible With a New Diagnosis of Glioblastoma

Fluorescence, Light-microscopy, Ultrasound Integrated / Intraoperative Diagnosis to MAXimise Resection

FLUID-MAX
Start date: April 8, 2022
Phase:
Study type: Observational

The present study aims to evaluate and compare with the histopathological analysis the various margin-assessment systems, including ultrasound, florescence, brightfield vision, new optical filters and microscope image post-processing systems, for the treatment of High Grade Gliomas (HGGs)

NCT ID: NCT05796856 Not yet recruiting - Retina Clinical Trials

Effect of Different Wavelengths of Repeated Low-Level Light Therapy on Choroidal and Retinal Blood Flow Among Adults

Start date: April 8, 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to evaluate the effect of different intensity of repeated low-level red-light (RLRL) therapy on the choroidal and retinal blood flow among adults.

NCT ID: NCT05807438 Not yet recruiting - Myofascial Spasm Clinical Trials

Comparison of the Immediate Effects of Physiotherapist and Self-administered Myofascial Release Techniques on Flexibility and Jumping Ability in Basketball Players

Start date: April 8, 2023
Phase: N/A
Study type: Interventional

Basketball is an aerobic-based anaerobic sport that calls for both high-intensity movements like jumping (for rebounds, blocks, and shots), spins, dribbling, sprinting, and screening and low-intensity movements like walking, stopping, and running.This sport requires sudden and fast movements where jumping performance is often a decisive factor for sporting success and Whether crouching in a defensive situation or throwing a long pass, a player needs to have a sufficient level of flexibility for adequate efficiency. Fascia connects the structures of the body with muscles, nerves and blood vessels. Limitations may occur due to injury. These limitations can reduce flexibility, strength, endurance and coordination.Therefore, this study aims to compare the acute effects of manual and self-myofascial release on flexibility and jump performance in basketball players. The secondary aim was to examine the acute improvements in flexibility and jump performance after myofascial therapy.

NCT ID: NCT05557331 Not yet recruiting - Clinical trials for Pediatric Emergency Medicine

Effectiveness of a Mobile App in Reducing Therapeutic TAT in an Emergency Department

Start date: April 8, 2024
Phase: N/A
Study type: Interventional

This study is a single center, non-equivalent comparison group, pre-post study in a tertiary pediatric emergency department in Switzerland. the study will compare the control and experimental groups on outcome measures before (12-month period) and after (6-month period) the intervention consisting of the implementation and use of the evidence-based mobile app-the ''Patients In My Pocket in my Hospital'' (PIMPmyHospital) app. The primary outcome will be the mean elapsed time in minutes between the delivery of lab results and the emergency department caregivers accessing them before (i.e., on the institutional electronic medical records) and after the implementation of the app (i.e, directly on the app).

NCT ID: NCT06270355 Not yet recruiting - Breast Cancer Clinical Trials

Stockholm Mammography Risk Stratified Trial

SMART
Start date: April 8, 2024
Phase: Phase 3
Study type: Interventional

SMART is a Phase III, randomised, non-blinded screening trial. Women who consent to participate in SMART are randomised to either individualised screening or screening according to the Swedish National Breast Cancer Screening Program. Women randomised to individualised screening get their 2-year risk of breast cancer assessed and women with the highest short-term risk are offered contrast enhanced mammography and a mammogram at 12 months.

NCT ID: NCT06332469 Not yet recruiting - Clinical trials for Chronic Kidney Diseases

Evaluation of an Internet Based Education and Support Program for Patients Awaiting Kidney Transplantation

INSERT
Start date: April 8, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to test the feasibility study of an internet based education and support program for patients awaiting kidney transplantation. The study is designed as a national pilot randomized controlled trial with a waitlist control group, to test the feasibility, acceptability, and potential effects of the intervention on patients' physical and mental health.

NCT ID: NCT06335940 Not yet recruiting - Clinical trials for Pediatric Respiratory Diseases

Admission for Respiratory Disease And VIdeo Regulation System

ARAVIS-PED
Start date: April 8, 2024
Phase:
Study type: Observational

Pediatric dyspnea is a major health problem, accounting for up to 27% of admissions to emergency departments in winter. It is estimated that a significant number (13%) of patients presenting to emergency departments are outpatients, at a time when emergency departments are having to cope with an ever-increasing flow of patients. Proper referral of patients calling the SAMU Centre-15 takes on its full meaning in this context, but regulating paediatric calls is more difficult. Indeed, the regulating doctor is most often in contact with the parents, who describe what they see and pass on their concerns, and it is difficult to have direct contact with patients who are often very young. Obtaining objective criteria such as saturation and respiratory rate is also a real challenge. To overcome the complexity of medical regulation, a number of tools and aids have been developed, including visio or video-regulation (regulation via the camera on the caller's smartphone). This device has been evaluated in a number of situations, enabling it to take its place in the daily practice of many doctors, but there is very little data concerning pediatric visio-regulation, particularly with regard to dyspnea. To the best of the investigator knowledge, there is no prospective study looking at the impact of Video-Regulation on the outcome of patients requiring the advice of SAMU Centre-15 for pediatric dyspnea.

NCT ID: NCT06336707 Not yet recruiting - Clinical trials for Advanced Solid Tumors

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

Start date: April 8, 2024
Phase: Phase 1
Study type: Interventional

HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6. This is a phase Ⅰ, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of HS-20089 in combination with other antitumor agents (Adebrelimab with or without platinum; Bevacizumab with or without platinum) in subjects with advanced solid tumors.